Rahul S. Patel

Rahul S. Patel

Auto-generated profile, based on publicly available information

Rahul S. Patel

Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2022 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
LYLindsay B. Young
Lindsay B. Young
PTParissa Tabrizian
Parissa Tabrizian
JSJeffrey Sung
Jeffrey Sung
DBDerek Biederman
Derek Biederman
VBVivian L. Bishay
Vivian L. Bishay
EKEdward Kim
Edward Kim

6 April 2015 in Clinical Imaging
Verified
Journal Article
Closed access
PDF file
VPVivek V. Patil
Vivek V. Patil
AFAaron Fischman
Aaron Fischman
RPRahul S. Patel
Rahul S. Patel
EKEdward Kim
Edward Kim
RLRobert A. Lookstein
Robert A. Lookstein
FNFrancis S. Nowakowski
Francis S. Nowakowski

4 July 2020 in Journal of American College Health
Verified
Journal Article
Closed access
RPRahul S. Patel
Rahul S. Patel
TWTanesha Walker
Tanesha Walker
ZWZachary T. Weber
Zachary T. Weber
SKSarah D. Kelley
Sarah D. Kelley
RHRyan Hansen
Ryan Hansen
Our pilot study tests whether university counseling centers (UCC) can apply the concept of cluster analysis, and geospatial analysis to identify clusters of “hot spots”. Participants: Study partici...

1 February 2023 in Seminars in Interventional Radiology
Verified
Journal Article
Open access
PDF file
ISIshan Sinha
Ishan Sinha
DGDaryl T. Goldman
Daryl T. Goldman
RPRahul S. Patel
Rahul S. Patel
FNFrancis S. Nowakowski
Francis S. Nowakowski
Portomesenteric decompression is often necessary to treat patients with refractory symptoms of portal hypertension. When transjugular or direct intrahepatic portosystemic shunt creation is not feasible or is inadequate, surgical portosystemic shunt creation is considered, which carries significant morbidity and mortality in these high-risk patients. Surgery is further complicated in patients with portomesenteric thrombosis who require concurrent thrombectomy and long-term anticoagulation. In this article, we outline the technique for performing advanced endovascular alternatives to intrahepatic portosystemic shunt creation including mesocaval and splenorenal shunting. We will also discuss some of the clinical considerations for treating these patients with symptomatic portal hypertension and portomesenteric thrombosis. Article published online: 04 May 2023 © 2023. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

29 October 2021
Verified
Book Chapter
Closed access
PDF file
SMShashidhara Murthy
Shashidhara Murthy
RPRahul S. Patel
Rahul S. Patel
AFAaron Fischman
Aaron Fischman

1 October 2026 in Annals of Surgery
Verified
Journal Article
Closed access
BTBenjamin Tran
Benjamin Tran
RMRebecca Marino
Rebecca Marino
JAJustine Aziz
Justine Aziz
JDJoseph DiNorcia
Joseph DiNorcia
JTJulia Torabi
Julia Torabi
PTParissa Tabrizian
Parissa Tabrizian
Objective: To establish the significance of complete pathologic response (cPR) on survival and locoregional treatment outcomes in a large US cohort. Background: cPR in hepatocellular carcinoma (HCC) is associated with improved post–liver transplant (LT) outcomes. cPR rates, modality-specific differences, and predictors remain undefined. Materials and Methods: Patients were identified from the United Network for Organ Sharing (UNOS) database (2012–2024). cPR was defined as the absence of a viable tumor on explant pathology. Logistic regression identified predictors of cPR, Fine-Gray models estimated the incidence of cPRand Kaplan-Meier analysis assessed survival. Results: Among 7398 LT recipients, 2167 (29.3%) achieved cPR. Imaging–pathology concordance was poor (30.5%), with imaging overestimating response in 42.6% of cases (κ=0.17, P 18 vs. <6 mo; odds ratio (OR): 1.94, 95% CI: 1.57–2.40], Y-90 (41.2%), and ablation (36.4%) were associated with higher cPR rates than transarterial chemoembolization (24.0%; P <0.001). On multivariable analysis, yttrium-90 (Y-90) [adjusted OR (aOR): 1.89, 95% CI: 1.46–2.05] and ablation (aOR: 1.23, 95% CI: 1.08–1.39) independently increased cPR, whereas greater tumor burden and elevated alpha-fetoprotein reduced cPR. Y-90 benefit was greatest when administered ≤6 months of waitlisting (OR: 2.40, 95% CI: 1.59–3.61) and in all-comer candidates (OR: 1.58, 95% CI: 1.17–3.26). Fine-Gray analysis confirmed the highest cumulative incidence of cPR with Y-90 across transplant eligibility criteria. cPR was associated with improved 5-year overall survival (86.6% vs. 77.4%) and recurrence-free survival (76.9% vs. 63.1%; P <0.001). Conclusions: Nearly one-third of LT recipients with HCC achieved cPR, which was associated with improved survival. Y-90 was independently associated with higher cPR rates, particularly when administered early and among patients with higher tumor burden.